This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Within lancelets === The notochord of the lancelet (amphioxus) protrudes beyond the anterior end of the neural tube. This projection serves a second purpose in allowing the animal to burrow within the sediment of shallow waters. There, amphioxus is a filter feeder and spends most of its life partially submerged within the sediment.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
=== China === The Government of China provides the funding for dialysis treatment. There is a challenge to reach everyone who needs dialysis treatment because of the unequal distribution of health care resources and dialysis centers. There are 395,121 individuals who receive hemodialysis or peritoneal dialysis in China per year. The percentage of the Chinese population with Chronic Kidney Disease is 10.8%. The Chinese Government is trying to increase the amount of peritoneal dialysis taking place to meet the needs of the nation's individuals with Chronic Kidney Disease.
==== Amputations ==== Save the Children reported 10 children a day in Gaza had lost their limbs, which would result in a lifetime of medical needs. A UNICEF spokesperson James Elder was quoted after returning from Gaza in mid-December 2023, that around 1,000 children had lost one or both legs since the 7 October attacks and the start of the war. According to the British doctor Ghassan Abu-Sittah, "This is the biggest cohort of pediatric amputees in history". In mid-December 2023, a teenager's amputation performed without anesthesia on her families kitchen table by her uncle who is a doctor went viral on social media. She and a sibling had climbed to the top of the building to call their father who is overseas before the building was reportedly struck by IDF tank fire, and she was rushed inside to her uncle. In early-January 2024, an 11-year-old speaking to reporters about her injuries which included an amputated leg and with the other severely injured expressed her hope in getting an artificial limb, and lamented how her life has become "ugly and sad" after the injury. Other children's stumps after amputation had to be re-opened after infections had set in. By June 2024, doctors in Gaza estimated as many as 3,000 children had lost limbs since October 2023. A WHO Emergency Medical Team coordinator also cautioned that due to lack of medical expertise and time, some of the amputations done were unnecessary or due to a time delay. The head of Humanity & Inclusion stated child amputees needed "immediate support" for prosthetics but that wasn't happening.
=== Molecular basis === Research has shown that there are more than 35 specific genetic disorders associated with arthrogryposis. Most of those mutations are missense, which means the mutation results in a different amino acid. Other mutations that could cause arthrogryposis are: single gene defects (X-linked recessive, autosomal recessive and autosomal dominant), mitochondrial defects and chromosomal disorders (for example: trisomy 18). This is mostly seen in distal arthrogryposis. Mutations in at least five genes (TNN12, TNNT3, TPM2, MYH3 and MYH8) could cause distal arthrogryposis. There could be also connective tissue, neurological or muscle development disorders.
Sources: en.wikipedia.org
In 1899 he was appointed assistant professor at West Virginia University. He moved to the McLean Hospital Boston in 1900 as a research biochemist, eventually moving to Harvard Medical School in 1907 as an associate professor of biological chemistry, becoming the Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology in 1909. Together with Vintilă Ciocâlteu Otto Folin designed the Folin-Ciocalteu reagent to detect polyphenols. In 1920, he co-developed with Hsien Wu the Folin-Wu method of assaying glucose in protein-free filtrates of blood. Folin was elected the president of the American Society of Biological Chemists (now the American Society for Biochemistry and Molecular Biology) in 1909. He was a member of the editorial board of the Journal of Biological Chemistry. He was elected to the National Academy of Sciences and was awarded the Carl Wilhelm Scheele Medal of the Swedish Chemical Society in 1930.
In the Catholic Church, the Dicastery for the Causes of Saints, previously named the Congregation for the Causes of Saints (Latin: Congregatio de Causis Sanctorum), is the dicastery of the Roman Curia that oversees the complex process that leads to the canonization of saints, passing through the steps of a declaration of "heroic virtues" and beatification. After preparing a case, including the approval of miracles, the case is presented to the pope, who decides whether or not to proceed with beatification or canonization.
== Diagnosis == The diagnosis is generally suspected when patients from certain ethnic groups (see epidemiology) develop anemia, jaundice, and symptoms of hemolysis after challenges from any of the above causes, especially when there is a positive family history. Generally, tests will include:
== Activation == Chymotrypsinogen must be inactive until it gets to the digestive tract, in order to prevent damage to the pancreas or any other organs. It is activated by another enzyme called trypsin. The active form is called π-chymotrypsin and is used to create α-chymotrypsin. Trypsin cleaves the peptide bond in chymotrypsinogen between arginine-15 and isoleucine-16. This creates two peptides within the π-chymotrypsin molecule, held together by a disulfide bond. One π-chymotrypsin acts on another by breaking a leucine and serine peptide bond. The activated π-chymotrypsin reacts with other π-chymotrypsin molecules to cleave and remove two dipeptides: serine-14–arginine-15 and threonine-147–asparagine-148. This reaction produces α-chymotrypsin. The yield of α-chymotrypsin can be affected by inhibitors such as hydrocinnate and also by pH, temperature and calcium chloride. The activation process can be studied using fluorescence probe 2-p-toluidinylnaphthalene-6-sulfonate (TNS). TNS forms covalent bonds with chymotrypsinogen and as the bonds break to form chymotrypsin in the presence of trypsin, the fluorescence increases.
Sources: en.wikipedia.org
G-protein-coupled receptor kinase 7 (EC 2.7.11.14, GRK7, cone opsin kinase, iodopsin kinase) is a serine/threonine-specific protein kinase involved in phototransduction. This enzyme catalyses the phosphorylation of cone (color) photopsins in retinal cones during high acuity color vision primarily in the fovea.
=== Koded solutions === These are solutions containing FSL Kode constructs where the construct will exist as a clear micellular dispersion. FSL-GB3 as a solution/gel has been used to inhibit HIV infection and to neutralise Shiga toxin. FSL blood group A as a solution has been used to neutralise circulating antibodies in a mouse model and allow incompatible blood group A (murine kodecytes) transfusion. This model experiment was used to demonstrate the potential of FSLs to neutralise circulating antibody and allow for incompatible blood transfusion or organ transplantation.
== Contraindications == Use of verapamil is generally avoided in people with severe left ventricular dysfunction, hypotension (systolic blood pressure less than 90 mm Hg), cardiogenic shock, and hypersensitivity to verapamil. It is also contraindicated in people with atrial flutter or fibrillation and an existing accessory tract such as in Wolff-Parkinson-White syndrome.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.